Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad Laboratories's total inventories for the quarter that ended in Jun. 2026 was €678 Mil. Bio-Rad Laboratories's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was €672 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bio-Rad Laboratories's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €-23.89.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bio-Rad Laboratories's Days Inventory for the
three
months ended in Jun. 2026 was 231.48.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bio-Rad Laboratories's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio-Rad Laboratories's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 1.19.
Bio-Rad Laboratories (FRA:BUWA) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Bio-Rad Laboratories's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio-Rad Laboratories's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Bio-Rad Laboratories Total Inventories Related Terms
Bio-Rad Laboratories Total Inventories Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Bio-Rad Laboratories (FRA:BUWA) has a Total Inventories of €678 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Total Inventories too high?
Bio-Rad Laboratories' current Total Inventories is €678 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Total Inventories compare to GKOS and BRKR?
Bio-Rad Laboratories' Total Inventories of €678 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Total Inventories is €678 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €276.51, compared to a current price of €303.00 — trading 9.6% above its estimated fair value. The current Total Inventories is €678 Mil. Bio-Rad Laboratories' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Total Inventories is €678 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €303.00 is trading 9.6% above its estimated GF Value™ of €276.51.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Total Inventories: €678 Mil
GF Value™: €276.51 vs. price of €303.00 (9.6% above fair value)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
75GF Score
Get the complete analysis for FRA:BUWA
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
